A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-02-24
Adverse events
Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2022-06-13 (study day 91); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 295); relationship: not assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 296); relationship: not assessed; serious criteria: hospitalization
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-30 (study day 381); relationship: N
Data queries
No data queries.